Articles by Eric B. Sheinin, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Eric B. Sheinin, PhD

Eric B. Sheinin, PhD


Eric Sheinin is the president of Sheinin and Associates, 13917 Bergenfield Dr., North Potomac, MD 20878, tel. 301.424.2606, fax 301.424.2831. He also is a member of Pharmaceutical Technologys editorial advisory board.

Articles
A Dubious Foundation for Quality Control
August 2, 2009

The author of an ambitious book about quality control falls short of reaching his goals.

USP's Semi-Hemiquinquennial Meeting
June 2, 2004

A recent USP gathering generated creative suggestions for the March 2005 USP convocation.

"A State of Revision: USP's Guideline for the Submission of Requests for Revision"
December 2, 2003

USP's new guideline will assist the industry to help set the monograph standards by which the industry must abide. This column suggests how to apply the guideline to gain maximum benefit.

Reflections on Changes at FDA
July 1, 2001

A former deputy director of the Office of Pharmaceutical Sciences takes a personal look back at 25 years of change at FDA's Center for Drug Evaluation and Research.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
FindPharma Custom Search
Click here